


[« Back to Pipeline](#)

COVID-19 Programs

Key Programs (Indication)	Phase
COVI-TRACE™ (diagnostic)	FDA EUA
COVI-STIX™ (diagnostic)	FDA EUA
COVI-TRACK™ – Platinum (diagnostic)	FDA EUA
COVI-GUARD™ (treatment)	Ph I
COVI-AMG™ (treatment)	Ph I
COVI-DROPS™ (treatment)	Preclinical
COVI-SHIELD™ (treatment)	Preclinical
COVIDTRAP™ (treatment)	Preclinical
ABIVERTINIB (treatment)	Ph II
SALICYN – 30 (treatment)	Preclinical
COVI-MSC (treatment)	Ph I

Immunotherapy

Key Programs (Indication)	Phase
CD38 CAR-T (Multiple Myeloma)	Ph I
CD38 DAR-T (Multiple Myeloma)	Preclinical
CD38 ADC (Amyloidosis)	Ph I
Seprehvir™ (Solid Tumors)	Ph I
Seprehvec™ (Solid Tumors)	Ph I
ABIVERTINIB (NSCLC)	PhIII/Pivotal
ADNIC (Solid and Liquid Tumors)	Ph II

Pain

Key Programs (Indication)	Phase
---------------------------	-------

RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain)

Ph II

RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA)

Ph II



Lymphatic Delivery

Key Programs (Indication)

Phase

Sofisa® anti-TNF (Autoimmune)

Ph I